|
AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update
|
13 Aug, 2019 |
|
AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock
|
18 Jul, 2019 |
|
AzurRx BioPharma Announces Proposed Public Offering of Common Stock
|
17 Jul, 2019 |
|
AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET
|
08 Jul, 2019 |
|
AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
|
08 Jul, 2019 |
|
AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers
|
07 Jun, 2019 |
|
AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial
|
23 May, 2019 |
|
AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference
|
20 May, 2019 |
|
AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial
|
23 Apr, 2019 |
|
Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights
|
02 Apr, 2019 |
|
AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference
|
18 Mar, 2019 |
|
AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20)
|
15 Mar, 2019 |
|
AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting
|
12 Mar, 2019 |
|
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
|
20 Feb, 2019 |
